# EDGAR Filing Document

**Accession Number:** 0001792267
**File Stem:** 0001193125-25-329450
**Filing Date:** 2025-12
**Character Count:** 4127
**Document Hash:** 75f631f1b7c5c818a6bbd2d431a7cc17
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-329450.hdr.sgml**: 20251223

**ACCESSION NUMBER**: 0001193125-25-329450

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251223

**FILED AS OF DATE**: 20251223

**DATE AS OF CHANGE**: 20251223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Burning Rock Biotech Ltd
- **CENTRAL INDEX KEY:** 0001792267
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39316
- **FILM NUMBER:** 251594598

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NO. 5 XINGDAO RING ROAD NORTH,
- **STREET 2:** INTERNATIONAL BIO ISLAND
- **CITY:** GUANGZHOU, GUANGDONG
- **PROVINCE COUNTRY:** F4
- **ZIP:** 510005
- **BUSINESS PHONE:** 86 18501641666

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NO. 5 XINGDAO RING ROAD NORTH,
- **STREET 2:** INTERNATIONAL BIO ISLAND
- **CITY:** GUANGZHOU, GUANGDONG
- **PROVINCE COUNTRY:** F4
- **ZIP:** 510005

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the month of December 2025** 

**Commission File Number: 001-39316** 

## BURNING ROCK BIOTECH LIMITED
**(Registrant's Name)** 

**No.5 Xingdao Ring Road North, International Bio Island** 

**Guangzhou, Guangdong** 

**People's Republic of China** 

**(Address of principal executive offices)** 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

------

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Number** | **Description of Document** |
| 99.1 | [Press release](d24155dex991.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Burning Rock Biotech Limited | Burning Rock Biotech Limited |
|  | By: | /s/ Yusheng Han |
|  | Name: | Yusheng Han |
|  | Title: | Chief Executive Officer |
| Date: December 23, 2025 |  |  |

---

## Exhibit 99.1

**Exhibit 99.1** 

**Burning Rock Announces Results of 2025 Annual General Meeting** 

GUANGZHOU, China, December 23, 2025—Burning Rock Biotech Limited (NASDAQ: BNR, the "**Company**" or "**Burning Rock**"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2025 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions:

1. as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the
Company for the fiscal year ending December 31, 2025 be ratified and that the directors of the Company be authorized to determine the remuneration of the auditor;

2. as an ordinary resolution, THAT Feng Deng and Licen Lisa Xu be re-elected as directors of the Company; and

3. as an ordinary resolution, THAT each of the directors of the Company be authorized to take any and all action
that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.

**About Burning Rock** 

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: ir.brbiotech.com.